Taiwan Liposome Co. Ltd., of Taipei, Taiwan, which is focused on developing nanomedicines for pain management, ophthalmology and oncology, said it filed a registration statement on form F-1 with the SEC for a proposed U.S. IPO of its American depositary shares (ADSs) representing shares of common stock. The company has applied to list its ADSs on Nasdaq under the trading symbol TLC.